LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 198

Search options

  1. Article ; Online: Cut-off value of clarithromycin resistance in the treatment of

    Hsu, Ping-I / Chuah, Seng-Kee / Yamaoka, Yoshio / Wu, Deng-Chyang

    Gut

    2024  Volume 73, Issue 2, Page(s) 374–375

    MeSH term(s) Humans ; Clarithromycin/pharmacology ; Clarithromycin/therapeutic use ; Helicobacter Infections/drug therapy ; Helicobacter pylori ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Amoxicillin/therapeutic use ; Drug Resistance, Bacterial ; Microbial Sensitivity Tests ; Metronidazole/therapeutic use ; Drug Therapy, Combination
    Chemical Substances Clarithromycin (H1250JIK0A) ; Anti-Bacterial Agents ; Amoxicillin (804826J2HU) ; Metronidazole (140QMO216E)
    Language English
    Publishing date 2024-01-05
    Publishing country England
    Document type Letter
    ZDB-ID 80128-8
    ISSN 1468-3288 ; 0017-5749
    ISSN (online) 1468-3288
    ISSN 0017-5749
    DOI 10.1136/gutjnl-2022-329253
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Ulceration caused by a persimmon bezoar.

    Chuah, Yoen Young / Lee, Yeong Yeh / Hsu, Ping-I

    British journal of hospital medicine (London, England : 2005)

    2023  Volume 84, Issue 9, Page(s) 1

    MeSH term(s) Humans ; Bezoars/complications ; Bezoars/diagnostic imaging ; Diospyros ; Intestinal Obstruction/etiology ; Fruit
    Language English
    Publishing date 2023-09-13
    Publishing country England
    Document type Journal Article
    ISSN 1750-8460
    ISSN 1750-8460
    DOI 10.12968/hmed.2023.0163
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Update on the first-line treatment of

    Shih, Chih-An / Shie, Chang-Bih / Hsu, Ping-I

    Therapeutic advances in gastroenterology

    2022  Volume 15, Page(s) 17562848221138168

    Abstract: Current international consensuses ... ...

    Abstract Current international consensuses on
    Language English
    Publishing date 2022-11-22
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2440710-0
    ISSN 1756-2848 ; 1756-283X
    ISSN (online) 1756-2848
    ISSN 1756-283X
    DOI 10.1177/17562848221138168
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: H. pylori infection and extra-gastroduodenal diseases.

    Tsay, Feng-Woei / Hsu, Ping-I

    Journal of biomedical science

    2018  Volume 25, Issue 1, Page(s) 65

    Abstract: Helicobacter pylori infection is the principal cause of peptic ulcer disease, gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue lymphoma. Recent studies have shown that it may interfere with many biological processes and determine or ... ...

    Abstract Helicobacter pylori infection is the principal cause of peptic ulcer disease, gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue lymphoma. Recent studies have shown that it may interfere with many biological processes and determine or influence the occurrence of many diseases outside the stomach. Currently, the role of H. pylori in idiopathic thrombocytopenic purpura and iron deficiency anemia is well documented. Emerging evidence suggests that it may also contribute to vitamin B12 deficiency, insulin resistance, metabolic syndrome, diabetes mellitus and non-alcoholic liver disease. Additionally, it may increase the risk of acute coronary syndrome, cerebrovascular disease, neurodegenerative disease and other miscellaneous disorders. Different pathogenic mechanisms have been hypothesized, including the occurrence of molecular mimicry and the induction of a low-grade inflammation. This review summarizes the results of the most relevant studies on the extra-gastroduodenal manifestations of H. pylori infection.
    MeSH term(s) Helicobacter Infections/complications ; Helicobacter Infections/microbiology ; Helicobacter pylori/physiology ; Humans
    Language English
    Publishing date 2018-08-29
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1193378-1
    ISSN 1423-0127 ; 1021-7770
    ISSN (online) 1423-0127
    ISSN 1021-7770
    DOI 10.1186/s12929-018-0469-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Second-line rescue treatment of

    Lin, Te-Fu / Hsu, Ping-I

    World journal of gastroenterology

    2018  Volume 24, Issue 40, Page(s) 4548–4553

    Abstract: At present, the best rescue therapy ... ...

    Abstract At present, the best rescue therapy for
    MeSH term(s) Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Drug Resistance, Bacterial ; Drug Therapy, Combination/methods ; Helicobacter Infections/drug therapy ; Helicobacter Infections/microbiology ; Helicobacter pylori/drug effects ; Helicobacter pylori/isolation & purification ; Humans ; Proton Pump Inhibitors/pharmacology ; Proton Pump Inhibitors/therapeutic use ; Treatment Failure
    Chemical Substances Anti-Bacterial Agents ; Proton Pump Inhibitors
    Language English
    Publishing date 2018-11-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2185929-2
    ISSN 2219-2840 ; 1007-9327
    ISSN (online) 2219-2840
    ISSN 1007-9327
    DOI 10.3748/wjg.v24.i40.4548
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Update on the second-line treatment of

    Shih, Chih-An / Shie, Chang-Bih / Tai, Wei-Chen / Chuah, Seng-Kee / Lee, Hsi-Chang / Hsu, Ping-I

    Therapeutic advances in gastroenterology

    2023  Volume 16, Page(s) 17562848231192750

    Abstract: A standard bismuth quadruple therapy, a fluoroquinolone-containing triple (or quadruple) therapy or a proton pump inhibitor (PPI)-amoxicillin high-dose dual therapy has been recommended as a second-line treatment ... ...

    Abstract A standard bismuth quadruple therapy, a fluoroquinolone-containing triple (or quadruple) therapy or a proton pump inhibitor (PPI)-amoxicillin high-dose dual therapy has been recommended as a second-line treatment for
    Language English
    Publishing date 2023-09-04
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2440710-0
    ISSN 1756-2848 ; 1756-283X
    ISSN (online) 1756-2848
    ISSN 1756-283X
    DOI 10.1177/17562848231192750
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.

    Hsu, Ping-I

    Journal of gastroenterology and hepatology

    2012  Volume 27, Issue 4, Page(s) 654–661

    Abstract: Patients taking antiplatelet agents for the prevention of cardiovascular diseases who develop gastrointestinal bleeding represent a serious challenge in clinical practice. The initial step in reducing gastrointestinal risk of antiplatelet therapy is to ... ...

    Abstract Patients taking antiplatelet agents for the prevention of cardiovascular diseases who develop gastrointestinal bleeding represent a serious challenge in clinical practice. The initial step in reducing gastrointestinal risk of antiplatelet therapy is to assess whether the patient has a continued need for antiplatelet therapy. The next step is to eliminate the risk factors that may place the patient at increased gastrointestinal risk. In the management of bleeding ulcer patients with high-risk stigmata of recent hemorrhage, resuming antiplatelet agents at 3-5 days after the last dosing is a reasonable strategy. However, patients with low-risk stigmata can keep taking antiplatelet agents immediately following endoscopy. In the management of aspirin-related uncomplicated peptic ulcers in patients requiring antiplatelet therapies, continuing aspirin plus a powerful proton pump inhibitor is the choice of treatment. Patients who require antiplatelet agents for the prevention of cardiovascular diseases should be tested and treated for Helicobacter pylori infection before starting antiplatelet therapy. Additionally, those with high risks for upper gastrointestinal bleeding should receive co-therapy with a gastroprotective drug, preferably a proton pump inhibitor at standard dose. H2-receptor antagonist can significantly reduce upper gastrointestinal bleeding risk in patients taking low-dose aspirin but it is ineffective in the prevention of upper gastrointestinal bleeding in clopidogrel users. Although several retrospective studies reported that patients prescribed clopidogrel who also took proton pump inhibitors had significant increases in cardiovascular events, the current evidence from a prospective randomized trial does not justify a conclusion that proton pump inhibitors are associated with cardiovascular events among clopidogrel users.
    MeSH term(s) Aspirin/adverse effects ; Aspirin/therapeutic use ; Cardiovascular Diseases/drug therapy ; Drug Interactions ; Gastrointestinal Hemorrhage/therapy ; Helicobacter Infections/drug therapy ; Helicobacter Infections/microbiology ; Helicobacter pylori ; Humans ; Peptic Ulcer/chemically induced ; Peptic Ulcer/drug therapy ; Peptic Ulcer/prevention & control ; Piperazines/adverse effects ; Piperazines/therapeutic use ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Aggregation Inhibitors/therapeutic use ; Prasugrel Hydrochloride ; Proton Pump Inhibitors/therapeutic use ; Thiophenes/adverse effects ; Thiophenes/therapeutic use ; Ticlopidine/adverse effects ; Ticlopidine/analogs & derivatives ; Ticlopidine/therapeutic use
    Chemical Substances Piperazines ; Platelet Aggregation Inhibitors ; Proton Pump Inhibitors ; Thiophenes ; clopidogrel (A74586SNO7) ; Prasugrel Hydrochloride (G89JQ59I13) ; Ticlopidine (OM90ZUW7M1) ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2012-04
    Publishing country Australia
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 632882-9
    ISSN 1440-1746 ; 0815-9319
    ISSN (online) 1440-1746
    ISSN 0815-9319
    DOI 10.1111/j.1440-1746.2012.07085.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Prevalence and risk factors for

    Chen, Yan-Hua / Jao, Tzu-Ming / Shiue, Yow-Ling / Feng, I-Jung / Hsu, Ping-I

    World journal of clinical cases

    2021  Volume 10, Issue 30, Page(s) 10896–10905

    Abstract: Background: Candida: Aim: To investigate the prevalence of CE among HIV-negative persons, and determine risk factors predicting CE.: Methods: Between January 2015 and December 2018, all consecutive outpatients who underwent routine ... ...

    Abstract Background: Candida
    Aim: To investigate the prevalence of CE among HIV-negative persons, and determine risk factors predicting CE.
    Methods: Between January 2015 and December 2018, all consecutive outpatients who underwent routine esophagogastroduodenoscopy as part of health check-ups at their own expense at the Health Check-up Center of the Kaohsiung Veterans General Hospital, Taiwan, were recruited in this study. Those with positive HIV serology results were excluded. Sociodemographic and clinical characteristics including age, gender, economic status, smoking history, alcohol consumption, tea and coffee consumption, underlying diseases, body fat percentage, body mass index, endoscopic findings, and
    Results: A total of 11802 participants were included in this study. Forty-seven (0.4%) were confirmed as having CE by pathological examination. Univariate analysis identified older age, the presence of chronic kidney disease, alcohol consumption, and steroid use (
    Conclusion: The prevalence of CE among HIV-negative persons was 0.4% in Taiwan. Independent risk factors for CE were older age, chronic kidney disease, alcohol consumption, and steroid use.
    Language English
    Publishing date 2021-09-21
    Publishing country United States
    Document type Journal Article
    ISSN 2307-8960
    ISSN 2307-8960
    DOI 10.12998/wjcc.v10.i30.10896
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Screening and prevention of hepatitis C virus reactivation during chemotherapy.

    Li, Yuan-Rung / Hu, Tsung-Hui / Chen, Wen-Chi / Hsu, Ping-I / Chen, Hui-Chun

    World journal of gastroenterology

    2021  Volume 27, Issue 31, Page(s) 5181–5188

    Abstract: Hepatitis C virus (HCV) reactivation occurs in 23% of HCV-infected cancer patients receiving chemotherapy. Forty-three percent of the patients with reactivation of HCV during chemotherapy develop a hepatitis flare. Most of the cancer patients with HCV ... ...

    Abstract Hepatitis C virus (HCV) reactivation occurs in 23% of HCV-infected cancer patients receiving chemotherapy. Forty-three percent of the patients with reactivation of HCV during chemotherapy develop a hepatitis flare. Most of the cancer patients with HCV reactivation have an unremarkable clinical course following an HCV-related hepatitis flare during chemotherapy. However, 26%-57% of the cancer patients developing an acute flare of chronic hepatitis C during chemotherapy require unanticipated discontinuation or dose reduction of chemotherapy, which results in deleterious changes in the cancer treatment plan. Although an optimal strategy for HCV screening in cancer patients receiving chemotherapy has not been established, universal pre-chemotherapy HCV testing for patients with hematological malignancies is recommended by current guidelines. All the currently approved direct-acting antivirals (DAAs) can be used in cancer patients, but the use of DAAs during chemotherapy should avoid drug-drug interactions between chemotherapy and antiviral agents. If there are no contraindications or anticipated drug-drug interactions, DAAs treatment can be administered before, during, or after chemotherapy. In conclusion, HCV reactivation occurs in approximately one-fourth of HCV-infected cancer patients receiving chemotherapy. An HCV-related hepatitis flare during chemotherapy may lead to the discontinuation of potentially life-saving chemotherapy. Currently, universal HCV screening is recommended in hematological malignancy patients before chemotherapy, but there is no evidence-based guideline for other cancer patients. DAAs treatment can cure HCV infection and prevent HCV reactivation during chemotherapy.
    MeSH term(s) Antiviral Agents/adverse effects ; Hepacivirus ; Hepatitis B, Chronic/drug therapy ; Hepatitis C/diagnosis ; Hepatitis C/drug therapy ; Hepatitis C, Chronic/drug therapy ; Humans ; Symptom Flare Up ; Virus Activation
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2021-09-08
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2185929-2
    ISSN 2219-2840 ; 1007-9327
    ISSN (online) 2219-2840
    ISSN 1007-9327
    DOI 10.3748/wjg.v27.i31.5181
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Application of serology in the diagnosis of Helicobacter pylori infection in patients with atrophic gastritis.

    Hsu, Ping-I

    Journal of the Chinese Medical Association : JCMA

    2010  Volume 73, Issue 11, Page(s) 561–562

    MeSH term(s) Antibodies, Bacterial/blood ; Enzyme-Linked Immunosorbent Assay ; Gastritis, Atrophic/microbiology ; Helicobacter Infections/diagnosis ; Helicobacter pylori/immunology ; Humans ; Immunoglobulin G/blood ; Serologic Tests
    Chemical Substances Antibodies, Bacterial ; Immunoglobulin G
    Language English
    Publishing date 2010-09-14
    Publishing country Netherlands
    Document type Comment ; Editorial
    ZDB-ID 2107283-8
    ISSN 1728-7731 ; 1726-4901
    ISSN (online) 1728-7731
    ISSN 1726-4901
    DOI 10.1016/S1726-4901(10)70123-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top